May 3, 2019

Myeloproliferative Neoplasms Update — Part 2: Our interview with Dr Gerds highlights the following topics and cases from his practice:

• Common misconceptions about MPNs (0:00)
• Alterations of the JAK-STAT signaling pathway in MPNs (1:43)
• Case: A 61-year-old woman with primary MF and mutations in JAK2, EZH2 and CALR receives ruxolitinib (4:29)
• Prognostic significance of the JAK2, EZH2 and CALR mutations associated with MF (7:20)
• Dosing and activity of ruxolitinib for MF (8:53)
• Management of ruxolitinib-associated cytopenias and effect of ruxolitinib on disease pathogenesis (12:19)
• Evolution of clinical research with the selective JAK2 inhibitor fedratinib for MF (15:32)
• Association between fedratinib and thiamine levels; cytopenias associated with fedratinib (17:20)
• Efficacy of fedratinib as second-line treatment for patients with disease progression on ruxolitinib (18:38)
• Risks and benefits associated with pacritinib therapy (20:00)
• Case: A 66-year-old man who presents with anemia is diagnosed with MF and a Type 1 CALR mutation (21:48)
• Risk of infections associated with ruxolitinib (23:12)
• Evaluation of ruxolitinib for the treatment of graft-versus-host disease (27:05)
• Activity of the JAK1/2 inhibitor momelotinib in patients with MF (28:23)
• Hepcidin suppression and improvement of anemia in patients with MF; effect of novel JAK inhibitors, including fedratinib and momelotinib (30:03)
• Results of the SIMPLIFY 2 study evaluating momelotinib versus best available therapy for patients with MF previously treated with ruxolitinib (32:28)
• Use of JAK inhibitors for rheumatoid arthritis (35:29)
• Novel agents and approaches under investigation for MPNs (36:48)
• Perspective on the potential role of venetoclax for patients with MPNs (40:30)
• Case: A 75-year-old woman previously diagnosed with ET and a JAK2 V617F mutation is found to have disease transformation to PV on reassessment 12 years later (43:34)
• Efficacy and side effects of the MDM2 antagonist idasanutlin in the treatment of PV (47:36)
• Importance of maintaining hematocrit control in patients with PV (50:15)
• Role of ruxolitinib for patients with PV (51:55)
• Case: A 45-year-old woman with persistent headaches is diagnosed with ET and a JAK2 V617F mutation (54:08)
• Therapeutic options for patients with ET (56:47)
• Perspective on the need for aspirin for ET (59:17)
• Role of interferon and PI3-kinase inhibitors in the treatment of MPNs (1:00:37)

Select publications